Free Trial

Innovent Biologics (IVBXF) News Today

Innovent Biologics logo
$5.09 +0.45 (+9.71%)
(As of 11/20/2024 ET)
Innovent Biologics Inc.
J.P. Morgan Keeps Their Buy Rating on Innovent Biologics (IVBXF)
Innovent Biologics says picankibart phase 2 study met primary endpoint
Get Innovent Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IVBXF and its competitors with MarketBeat's FREE daily newsletter.

2024 Election Year Stocks: Uncover Hidden Gems! (Ad)

In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.

Secure your copy now by clicking this link.

IVBXF Media Mentions By Week

IVBXF Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IVBXF
News Sentiment

0.00

0.47

Average
Medical
News Sentiment

IVBXF News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IVBXF Articles
This Week

0

1

IVBXF Articles
Average Week

Get Innovent Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IVBXF and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (OTCMKTS:IVBXF) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners